REPR -- profitable, cash-rich, rapidly growing, recession-proof, tiny float OS & market cap with a juicy FDA approval pending any week...
Management is so confident of continued much higher profits than last quarter going forward that they have set aside a "deferred tax asset" in the balance sheet "based the valuation allowance calculations on the prospect of future profitability" http://pinksheets.com/edgar/GetFilingHtml?FilingID=6632631
Based on seasonal & cylical patterns as well as their recent hiring and doubling of shifts and landing business with a huge hospital & the pending FDA approval, I suspect REPR is 1 or 2 quarters away from +.02 EPS per quarter or more or an annualized +.08 EPS pace IMO. 10 PE = .80/share, 15 PE = $1.20/share. 20 PE = $1.80/share